HCV lookback proposed rule
This article was originally published in The Gray Sheet
FDA's Center for Biologics Evaluation & Research intends to issue a proposed rule making the hepatitis C virus lookback program a requirement for blood establishments and health care providers, instead of relying on voluntary compliance with a Sept. 23 revised guidance ("The Gray Sheet, Sept. 28, p. 13). The lookback covers patients who may have received HCV-contaminated blood or blood products between 1988 and 1992. The rule is not anticipated to differ substantively from the guidance, which says blood establishments must begin to notify blood "consignees" (hospitals, transfusion services, physicians, etc.) about contaminated blood or blood products by March 23, 1999, and finish by March 23, 2000. Transfusion services must then notify recipients by March 23, 2001
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.